TIMP1 and metabolic dysfunction-associated steatohepatitis: Finally, we tested other genes in the SMAD pathway and showed that the treatment with artemether significantly decreased fibrogenic gene expressions in the NASH mouse liver, including smad2, Timp1, and Actaα (Figure 7H).